BioVersys Aktie
WKN DE: A410LA / ISIN: CH0210362643
|
05.11.2025 07:00:04
|
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
|
BioVersys AG
/ Key word(s): Conference
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today that management will present BioVersys latest clinical and preclinical developments and meet with Institutional Investors at the upcoming Stifel 2025 Annual Healthcare Conference that will take place on November 11-13, 2025 at the Lotte New York Palace Hotel in New York City.
Details:
BioVersys management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About BioVersys BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. BioVersys contact Hernan Levett, CFO, Tel. +41 61 633 22 50; Mail: Hernan.levett@bioversys.com For Media: media@bioversys.com
End of Media Release |
2223448 05.11.2025 CET/CEST
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioVersysmehr Nachrichten
|
07:00 |
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network (EQS Group) | |
|
07.11.25 |
SIX-Handel SPI zeigt sich am Freitagmittag schwächer (finanzen.at) | |
|
06.11.25 |
Börse Zürich in Rot: SPI schlussendlich in Rot (finanzen.at) | |
|
06.11.25 |
Zurückhaltung in Zürich: So entwickelt sich der SPI aktuell (finanzen.at) | |
|
06.11.25 |
Anleger in Zürich halten sich zurück: SPI fällt mittags (finanzen.at) | |
|
06.11.25 |
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA (EQS Group) | |
|
05.11.25 |
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york (EQS Group) | |
|
04.11.25 |
Börse Zürich in Rot: SPI verbucht zum Handelsstart Abschläge (finanzen.at) |
Analysen zu BioVersysmehr Analysen
Aktien in diesem Artikel
| BioVersys | 25,40 | -3,79% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.